Allysta is dedicated to developing innovative new medicines for unmet needs directed towards novel first-in-class targets. We proceed from the principle that breakthrough therapies have the greatest chance of success when they are built upon a strong scientific foundation. We seek to be science-driven and results-focused.
Allysta Pharmaceuticals is a private clinical stage biopharmaceutical company based in the San Francisco Bay Area. We are developing first-in-class therapeutic peptides that uniquely target adiponectin signaling pathways. Adiponectin, a natural protein whose receptors are widely distributed, has multiple beneficial actions, including anti-inflammatory, anti-fibrotic, anti-steatotic, and cell regenerative properties; it also plays a critical role in maintaining metabolic energy balance at the cellular and organism level and reverses insulin resistance. Our lead drug, ALY688, is a potent and specific agonist (activator) of adiponectin receptor signaling well suited for development as a novel therapeutic. Our first indication for Aly688 is a topical eye drop for treatment of inflammatory ocular surface disorders, particularly dry eye disease. We have shown that ALY688's anti-inflammatory and cell regenerative actions very effectively reduces inflammation and enhances corneal cell repair. Allysta is also developing ALY688 for systemic administration and we are targeting inflammatory liver diseases such as NASH (non-alcoholic steatohepatitis), where the multimodal actions of adiponectin activation are ideally suited.
Ocular Surface Inflammation
Developing Innovative Medicines
(Fatty Liver Disease;